ARTHROPLASTY
Preop oral TXA demonstrates noninferiority to IV TXA in TKA for hemostasis
J Arthroplasty. 2016 Sep;31(9 Suppl):26-3078 patients scheduled for total knee arthroplasty were randomized to be administered oral or intravenous tranexamic acid (TXA). The purpose of this study was to determine if oral TXA, which costs less, was noninferior to IV TXA. Outcomes included postoperative hemoglobin drop, total blood loss, postoperative drainage volume, transfusion rate, and the incidence of thromboembolic complications. Equivalence testing for hemoglobin drop and total blood loss demonstrated noninferior efficacy of oral TXA compared to IV TXA.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
